Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
NovaBridge's majority-owned subsidiary Visara licensed exclusive worldwide rights (excluding Greater China) to VIS-102, an investigational nerve growth factor therapy for neurotrophic keratitis, from Wuhan Hiteck Biological Pharma. Phase 1b data in Chinese patients with severe NK showed 50% complete corneal healing in the highest dose cohort after a single 8-week course versus 14% in the vehicle control group, with only mild ocular adverse events.
Key figures
- Drug Name
- VIS-102 (HT006.2.2)
- Phase Of Trial
- Phase 1b
- Crossover healing rate
- 43% after 4-week course
- Healing rate highest dose
- 50% complete corneal healing after single 8-week course
- Healing rate vehicle control
- 14% at Week 4
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.